Apr 22, 2016

Posted by in Biotech Stocks | 0 Comments

Investor’s Alert: PDL BioPharma Inc (NASDAQ:PDLI), BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), Immunomedics Inc (NASDAQ:IMMU)

Investor’s Alert: PDL BioPharma Inc (NASDAQ:PDLI), BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), Immunomedics Inc (NASDAQ:IMMU)

PDL BioPharma Inc (NASDAQ:PDLI) stock is at $3.74. The stock opened the session at $3.73 and touched its highest price point at $3.80. The company’s stock’s lowest price point for the session stood at $3.68. Its yesterday’s volume was 1.97 million shares in comparison to its usual trading volume of 2.24 million shares.

PDL BioPharma Inc (NASDAQ:PDLI) on March 31, 2016 announced that the Company will hold its annual meeting of stockholders on Thursday, June 2, 2016, at 10:00 a.m. Pacific Time for all stockholders of record on April 8, 2016. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has committed over $1 billion and funded approximately $937 million in these investments to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on acquiring new income generating assets, the management of its intellectual property and income generating assets, and maximizing value for its stockholders.

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) stock is at $3.36, up +7.35 percent from its previous close of $3.13. Its yesterday’s volume was 1.94 million shares in comparison to its usual trading volume of 1.13 million shares. Previous 5 days graph demonstrated a positive move of 13.13%. Its quarterly performance remained red with the percentage of -52.2, while its year to date performance showed that the stock plunged overall -67.97%.

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) on April 21, 2016 announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016.  BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company’s clinical development programs.  The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.  BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including avoralstat, BCX7353 and other second generation compounds; and BCX4430, a broad spectrum viral RNA polymerase inhibitor.

Immunomedics Inc (NASDAQ:IMMU) traded in the range of $2.95 and $3.08 in its previous trading session. The stock recorded the volume of 1.85 million shares so far, in comparison its average daily trading volume of 722,350.00 shares. Company’s year to date performance remained declining as it lost almost -1.31%. The stock opened at $2.95 and its closing price for the day was $3.08, up 1.35 percent from its previous close.

Immunomedics Inc (NASDAQ:IMMU) on April 20, 2016 announced the issuance of U.S. Patent No. 9,315,567 to its majority-owned subsidiary, IBC Pharmaceuticals, Inc., for a new patent family “T-Cell Redirecting Bispecific Antibodies for Treatment of Disease,” which will expire in August 2033.

The new invention concerns methods of use of T-cell redirecting bispecific antibodies, created with the Company’s proprietary DOCK-AND-LOCK® (DNL®) protein conjugation platform technology. The issued claims cover use of DNL® complexes that simultaneously bind to the CD3 T-cell antigen and the Trop-2 tumor antigen, which is expressed by many solid cancers. The claims specifically cover use of the Company’s proprietary (E1)-3s bispecific antibody.

The use of bispecific antibodies to redirect T cells for the killing of targeted tumor cells has shown considerable promise both preclinically and clinically. The Company has previously reported preclinical results that showed (E1)-3s effectively induced T-cell redirected killing of pancreatic and gastric cancer cell lines.1 Furthermore, interferon-alpha significantly improved (E1)-3s-mediated T-cell killing of human gastric and pancreatic cancer cells both in vitro and in vivo.2

More importantly, (E1)-3s was highly active without inducing high-level production of secondary cytokines, thereby reducing the risk of cytokine release syndrome, also known as cytokine storm, which is often associated with immunotherapy using T-cell-directed antibodies.

 

Comments are closed.